Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH Focus on Leukemia 2020 | Treating AML patients who are not eligible for intensive chemotherapy

Thomas Prebet, MD, Yale School of Medicine, New Haven, CT, discusses the challenge of treating acute myeloid leukemia (AML) patients who are not eligible for intensive chemotherapy. These patients are generally not eligible for transplantation either. The use of BCL-2 inhibitors and targeted therapies can be beneficial. Combining different agents needs to be investigated to maximize results while still upholding the patients’ quality of life. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Disclosures

Thomas Prebet, MD, has done consultancy work and received research support from Otsuka, Genentech, Abbvie and Jazz Pharma.